Now showing items 1-6 of 6

    • ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A. 

      Williamson, CT; Miller, R; Pemberton, HN; Jones, SE; Campbell, J; Konde, A; Badham, N; Rafiq, R; Brough, R; Gulati, A; Ryan, CJ; Francis, J; Vermulen, PB; Reynolds, AR; Reaper, PM; Pollard, JR; Ashworth, A; Lord, CJ (2016-12-13)
      Identifying genetic biomarkers of synthetic lethal drug sensitivity effects provides one approach to the development of targeted cancer therapies. Mutations in ARID1A represent one of the most common molecular alterations ...
    • Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma. 

      Kuczynski, EA; Yin, M; Bar-Zion, A; Lee, CR; Butz, H; Man, S; Daley, F; Vermeulen, PB; Yousef, GM; Foster, FS; Reynolds, AR; Kerbel, RS (2016-08)
      The anti-angiogenic Sorafenib is the only approved systemic therapy for advanced hepatocellular carcinoma (HCC). However, acquired resistance limits its efficacy. An emerging theory to explain intrinsic resistance to other ...
    • Imaging biomarker roadmap for cancer studies. 

      O'Connor, JPB; Aboagye, EO; Adams, JE; Aerts, HJWL; Barrington, SF; Beer, AJ; Boellaard, R; Bohndiek, SE; Brady, M; Brown, G; Buckley, DL; Chenevert, TL; Clarke, LP; Collette, S; Cook, GJ; deSouza, NM; Dickson, JC; Dive, C; Evelhoch, JL; Faivre-Finn, C; Gallagher, FA; Gilbert, FJ; Gillies, RJ; Goh, V; Griffiths, JR; Groves, AM; Halligan, S; Harris, AL; Hawkes, DJ; Hoekstra, OS; Huang, EP; Hutton, BF; Jackson, EF; Jayson, GC; Jones, A; Koh, D-M; Lacombe, D; Lambin, P; Lassau, N; Leach, MO; Lee, T-Y; Leen, EL; Lewis, JS; Liu, Y; Lythgoe, MF; Manoharan, P; Maxwell, RJ; Miles, KA; Morgan, B; Morris, S; Ng, T; Padhani, AR; Parker, GJM; Partridge, M; Pathak, AP; Peet, AC; Punwani, S; Reynolds, AR; Robinson, SP; Shankar, LK; Sharma, RA; Soloviev, D; Stroobants, S; Sullivan, DC; Taylor, SA; Tofts, PS; Tozer, GM; van Herk, M; Walker-Samuel, S; Wason, J; Williams, KJ; Workman, P; Yankeelov, TE; Brindle, KM; McShane, LM; Jackson, A; Waterton, JC (2017-03)
      Imaging biomarkers (IBs) are integral to the routine management of patients with cancer. IBs used daily in oncology include clinical TNM stage, objective response and left ventricular ejection fraction. Other CT, MRI, PET ...
    • Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma. 

      Bridgeman, VL; Wan, E; Foo, S; Nathan, MR; Welti, JC; Frentzas, S; Vermeulen, PB; Preece, N; Springer, CJ; Powles, T; Nathan, PD; Larkin, J; Gore, M; Vasudev, NS; Reynolds, AR (2016-01)
      Sunitinib and pazopanib are antiangiogenic tyrosine kinase inhibitors (TKI) used to treat metastatic renal cell carcinoma (RCC). However, the ability of these drugs to extend progression-free and overall survival in this ...
    • Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models. 

      Bridgeman, VL; Vermeulen, PB; Foo, S; Bilecz, A; Daley, F; Kostaras, E; Nathan, MR; Wan, E; Frentzas, S; Schweiger, T; Hegedus, B; Hoetzenecker, K; Renyi-Vamos, F; Kuczynski, EA; Vasudev, NS; Larkin, J; Gore, M; Dvorak, HF; Paku, S; Kerbel, RS; Dome, B; Reynolds, AR (2017-02)
      Anti-angiogenic therapies have shown limited efficacy in the clinical management of metastatic disease, including lung metastases. Moreover, the mechanisms via which tumours resist anti-angiogenic therapies are poorly ...
    • Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases. 

      Frentzas, S; Simoneau, E; Bridgeman, VL; Vermeulen, PB; Foo, S; Kostaras, E; Nathan, M; Wotherspoon, A; Gao, Z-H; Shi, Y; Van den Eynden, G; Daley, F; Peckitt, C; Tan, X; Salman, A; Lazaris, A; Gazinska, P; Berg, TJ; Eltahir, Z; Ritsma, L; Van Rheenen, J; Khashper, A; Brown, G; Nystrom, H; Sund, M; Van Laere, S; Loyer, E; Dirix, L; Cunningham, D; Metrakos, P; Reynolds, AR (2016-11)
      The efficacy of angiogenesis inhibitors in cancer is limited by resistance mechanisms that are poorly understood. Notably, instead of through the induction of angiogenesis, tumor vascularization can occur through the ...